Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Publisher
Journal of the American College of Cardiology(2)
European Heart Journal - Cardiovascular Pharmacotherapy(1)
Área temáticas
Enfermedades(3)
Farmacología y terapéutica(3)
Cirugía y especialidades médicas afines(1)
Fisiología humana(1)
Área de conocimiento
Medicina interna(2)
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
ArticleAbstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,Palabras claves:Cardiovascular Risk, DOAC, prevention, rivaroxabanAutores:Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.Fuentes:googlescopus